5WUX
 
 | | TNFalpha-certolizumab Fab | | 分子名称: | Tumor necrosis factor alpha, heavy, light | | 著者 | Heo, Y.S, Lee, J.U. | | 登録日 | 2016-12-21 | | 公開日 | 2017-06-07 | | 実験手法 | X-RAY DIFFRACTION (2.9 Å) | | 主引用文献 | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Int J Mol Sci, 18, 2017
|
|
5WUV
 | | Crystal structure of Certolizumab Fab | | 分子名称: | heavy chain, light chain | | 著者 | Heo, Y.S, Lee, J.U, Son, J.Y, Shin, W, Yoo, K.Y. | | 登録日 | 2016-12-21 | | 公開日 | 2017-06-07 | | 実験手法 | X-RAY DIFFRACTION (1.952 Å) | | 主引用文献 | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Int J Mol Sci, 18, 2017
|
|
4Y7I
 | | Crystal Structure of MTMR8 | | 分子名称: | Myotubularin-related protein 8, PHOSPHATE ION | | 著者 | Yoo, K, Lee, J, Son, J, Shin, W, Im, D, Heo, Y.S. | | 登録日 | 2015-02-15 | | 公開日 | 2015-07-15 | | 最終更新日 | 2024-03-20 | | 実験手法 | X-RAY DIFFRACTION (2.802 Å) | | 主引用文献 | Structure of the catalytic phosphatase domain of MTMR8: implications for dimerization, membrane association and reversible oxidation.
Acta Crystallogr.,Sect.D, 71, 2015
|
|
5GGU
 | | Crystal structure of tremelimumab Fab | | 分子名称: | heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (2.292 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGS
 | | PD-1 in complex with pembrolizumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.997 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGV
 | | CTLA-4 in complex with tremelimumab Fab | | 分子名称: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.998 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGT
 | | PD-L1 in complex with BMS-936559 Fab | | 分子名称: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2024-03-20 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGR
 | | PD-1 in complex with nivolumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (3.3 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGQ
 | | Crystal structure of Nivolumab Fab fragment | | 分子名称: | nivolumab heavy chain, nivolumab light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5Y9J
 | | BAFF in complex with belimumab | | 分子名称: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | | 著者 | Heo, Y.-S, Shin, W. | | 登録日 | 2017-08-25 | | 公開日 | 2018-02-21 | | 最終更新日 | 2019-09-04 | | 実験手法 | X-RAY DIFFRACTION (2.05 Å) | | 主引用文献 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
5Y9K
 | | Structure of the belimumab Fab fragment | | 分子名称: | belimumab heavy chain, belimumab light chain | | 著者 | Heo, Y.-S, Shin, W. | | 登録日 | 2017-08-25 | | 公開日 | 2018-02-21 | | 最終更新日 | 2019-09-04 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
